• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Nuwellis Inc.

    10/20/22 4:19:50 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NUWE alert in real time by email
    SC 13G 1 sched13g.htm
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No.   )*
     

     
    Nuwellis, Inc.
     
     
    (Name of Issuer)
     

     
    Common Stock, par value $0.0001 per share
     
     
    (Title of Class of Securities)
     

     
    67113Y108
     
     
    (CUSIP Number)
     

     
    October 20, 2022
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [ ]            Rule 13d-1(b)
    [x]            Rule 13d-1(c)
    [ ]            Rule 13d-1(d)
    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


     
    1
     
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
    Lind Global Fund II LP
     
     
    2
     
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
     
    (a)            [ ]
     
     
    (b)            [x]
     
    3
     
    SEC Use Only
     
    4
     
    Citizenship or Place of Organization.
     
    Delaware
     

     
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
     
    5  Sole Voting Power
    2,550,000
     
    6  Shared Voting Power
     
    0
     
    7  Sole Dispositive Power
     
    2,550,000
     
    8  Shared Dispositive Power
     
    0

     
    9
     
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    2,550,000(1)
     
     
    10
     
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
     
    11
     
    Percent of Class Represented by Amount in Row (9)*
     
    8.1%(2)
     
     
    12
     
    Type of Reporting Person (See Instructions)
    PN
     
    (1) The reporting person’s ownership consists of (i) 2,550,000 common shares, (ii) 1,049,280 shares of Series I Preferred Stock (the “Preferred Stock”) and (iii) 5,398,930 warrants to purchase common shares (“Warrants”); however, due to the conversion limitations of the Preferred Stock and exercise limitations of the Warrants, the reporting person’s beneficial ownership of the Preferred Stock and Warrants is excluded.
    (2) The certificate of designations for the Preferred Stock includes a provision limiting the holder’s ability to convert the Preferred Stock if such conversion would cause the holder to beneficially own greater than 4.99% of the Company.  Each of the Warrants includes a provision limiting the holder’s ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 4.99% of the Company.


     
    1
     
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
    Lind Global Partners II LLC
     
     
    2
     
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
     
    (a)            [ ]
     
     
    (b)            [x]
     
    3
     
    SEC Use Only
     
    4
     
    Citizenship or Place of Organization.
     
    Delaware
     

     
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
     
    5  Sole Voting Power
     
    2,550,000
     
    6  Shared Voting Power
     
    0
     
    7  Sole Dispositive Power
     
    2,550,000
     
    8  Shared Dispositive Power
     
    0

     
    9
     
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    2,550,000(1)
     
     
    10
     
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
     
    11
     
    Percent of Class Represented by Amount in Row (9)*
     
    8.1%(2)
     
     
    12
     
    Type of Reporting Person (See Instructions)
    OO
     
    (1) The reporting person’s ownership consists of (i) 2,550,000 common shares, (ii) 1,049,280 shares of Preferred Stock and (iii) 5,398,930 Warrants; however, due to the conversion limitations of the Preferred Stock and exercise limitations of the Warrants, the reporting person’s beneficial ownership of the Preferred Stock and Warrants is excluded.
    (2) The certificate of designations for the Preferred Stock includes a provision limiting the holder’s ability to convert the Preferred Stock if such conversion would cause the holder to beneficially own greater than 4.99% of the Company.  Each of the Warrants includes a provision limiting the holder’s ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 4.99% of the Company.



     
    1
     
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Jeff Easton
     
    2
     
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
     
    (a)            [ ]
     
     
    (b)            [x]
     
    3
     
    SEC Use Only
     
    4
     
    Citizenship or Place of Organization.
     
    United States
     

     
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
     
    5  Sole Voting Power
     
    2,550,000
     
    6  Shared Voting Power
     
    0
     
    7  Sole Dispositive Power
     
    2,550,000
     
    8  Shared Dispositive Power
     
    0

     
    9
     
    Aggregate Amount Beneficially Owned by Each Reporting Person
    2,550,000(1)
     
     
    10
     
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
     
    11
     
    Percent of Class Represented by Amount in Row (9)*
     
    8.1%(2)
     
     
    12
     
    Type of Reporting Person (See Instructions)
     
    IN
     
     
    (1) The reporting person’s ownership consists of (i) 2,550,000 common shares, (ii) 1,049,280 shares of Preferred Stock and (iii) 5,398,930 Warrants; however, due to the conversion limitations of the Preferred Stock and exercise limitations of the Warrants, the reporting person’s beneficial ownership of the Preferred Stock and Warrants is excluded.
    (2) The certificate of designations for the Preferred Stock includes a provision limiting the holder’s ability to convert the Preferred Stock if such conversion would cause the holder to beneficially own greater than 4.99% of the Company.  Each of the Warrants includes a provision limiting the holder’s ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 4.99% of the Company.




    Item 1.
    (a)
    Name of Issuer
     
     
    Nuwellis, Inc.
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    12988 Valley View Road
    Eden Prairie, MN 55344
     

    Item 2.
    (a)
    Name of Person Filing
     
     
    This statement is filed by the following entities and individuals (collectively, referred to as the “Reporting Persons”):
     
    •   Lind Global Fund II LP, a Delaware limited partnership;
    •   Lind Global Partners II LLC, a Delaware limited liability company; and
    •   Jeff Easton, an individual and a citizen of the United States of America.
     
    Lind Global Partners II LLC, the general partner of Lind Global Fund II LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    Jeff Easton, the managing member of Lind Global Partners II LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    The address of the principal business office for each of the Reporting Persons is:
     
    444 Madison Ave, Floor 41
    New York, NY 10022
     
    (c)
    Citizenship
     
     
    See Row 4 of cover page for each Reporting Person.
     
    (d)
    Title of Class of Securities
     
     
    Common Stock, $0.0001 par value per share

    (e)
    CUSIP Number
     
     
    67113Y108
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    Not applicable.
    Item 4.
    Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a)
    Amount Beneficially Owned
     
     
     See Row 9 of cover page for each Reporting Person.
     
    (b)
    Percent of Class
     
     
    See Row 11 of cover page for each Reporting Person.
     

    (c)
    Number of shares as to which such person has:
     
     
    (i)
    sole power to vote or to direct the vote
       

    See Row 5 of cover page for each Reporting Person.
     
     
    (ii)
    shared power to vote or to direct the vote
       
     
    See Row 6 of cover page for each Reporting Person.
     
     
    (iii)
    sole power to dispose or to direct the disposition of
       

    See Row 7 of cover page for each Reporting Person.
     
     
    (iv)
    shared power to dispose or to direct the disposition of
       
     
    See Row 8 of cover page for each Reporting Person.
     

    Item 5.
    Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person
    Not applicable.
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group
    Not applicable.
    Item 9.
    Notice of Dissolution of Group
    Not Applicable.
    Item 10.
    Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Exhibits     Exhibit

    99.1                  Joint Filing Agreement by and among the Reporting Persons.



    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    October 20, 2022
    LIND GLOBAL FUND II LP
       
    By:
     
    Lind Global Partners II LLC
     
     
    its General Partner
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    LIND GLOBAL PARTNERS II LLC
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    JEFF EASTON
     
    By:
     
    /s/ Jeff Easton


    Get the next $NUWE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NUWE

    DatePrice TargetRatingAnalyst
    7/29/2024$17.00Buy
    ROTH MKM
    More analyst ratings

    $NUWE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Mccormick Michael Kendrick

      4 - Nuwellis, Inc. (0001506492) (Issuer)

      1/4/24 4:25:39 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Mcdonald David

      4 - Nuwellis, Inc. (0001506492) (Issuer)

      1/4/24 4:21:51 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Feldshon Archelle Georgiou

      4 - Nuwellis, Inc. (0001506492) (Issuer)

      1/4/24 4:16:08 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NUWE
    Financials

    Live finance-specific insights

    See more
    • Nuwellis, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

      MINNEAPOLIS, May 13, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a commercial-stage medical device company dedicated to transforming care for fluid overload patients, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. First Quarter 2025 and Recent Business Highlights Nuwellis continued to advance its strategic priorities during the first quarter, delivering growth in customer categories and strengthening the foundation for broader adoption of Aquadex therapy. Higher CMS reimbursement, strong pediatric performance, and disciplined expense management position the company to capitalize on both inpatient growth and em

      5/13/25 7:00:00 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis, Inc. To Report First Quarter 2025 Financial Results on May 13, 2025

      MINNEAPOLIS, April 22, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a commercial-stage medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the first quarter 2025 on May 13, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-579-2543 (U.S) or 1-785-424-1789 (international) and using the conference ID: NUWEQ1. An a

      4/22/25 4:04:59 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results

      MINNEAPOLIS, March 11, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a commercial-stage medical device company focused on transforming the lives of people with fluid overload, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights: CMS four-fold payment increase to $1,639 for Aquadex Ultrafiltration Therapy in the outpatient setting effective January 1, 2025.New data published in JACC: Heart Failure showed Aquadex ultrafiltration reduced heart failure events by 60% compared to IV diuretics.Full year operating cost reduction of $5.9 million, or 26%, compared to the pr

      3/11/25 8:00:00 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NUWE
    SEC Filings

    See more
    • SEC Form 10-Q filed by Nuwellis Inc.

      10-Q - Nuwellis, Inc. (0001506492) (Filer)

      5/13/25 5:00:43 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Nuwellis, Inc. (0001506492) (Filer)

      5/13/25 11:00:41 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Nuwellis, Inc. (0001506492) (Filer)

      5/12/25 4:45:22 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NUWE
    Leadership Updates

    Live Leadership Updates

    See more
    • Nuwellis Announces Retirement of Nestor Jaramillo, Jr. as President and CEO

      MINNEAPOLIS, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that Nestor Jaramillo, Jr. retired as President and Chief Executive Officer and as a director of the company, effective February 18, 2025. John Erb, who currently serves as Chairman of the company's Board of Directors, assumed the role of Interim President and Chief Executive Officer and assumed all of the duties formerly performed by Mr. Jaramillo. Nuwellis intends to retain an executive search firm to assist in identifying a permanent CEO. Mr. Erb, stated, "Nestor has been with the company for nearly si

      2/24/25 4:05:00 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis Announces Board of Directors Transition

      MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the appointment of Dave McDonald and Archelle Georgiou, MD, to its board of directors, effective November 1, 2023. "With decades of experience and leadership in their respective fields, we welcome Dave and Archelle to our board. Dave's significant experience in finance and strategy will provide key insights to our board as we advance our growth and expansion initiatives. In turn, our board will benefit from perspectives gained from Archelle's healthcare policy, clinical, and patient education experience

      11/1/23 8:00:00 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis Announces the Appointment of Mike McCormick to its Board of Directors

      MINNEAPOLIS, June 05, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of patients suffering from fluid overload, today announced that Mike McCormick has been appointed to the company's Board of Directors. Mr. McCormick's vast experience includes more than 25 years of service in the medical device industry through varying leadership roles for several private and publicly traded companies. Mr. McCormick will also serve as Lead Independent Director and serve as a member of the Audit Committee and as Chair of the Nominating and Corporate Governance Committee of the Board. "We are delighted to welcome Mike to Nuwellis' Board

      6/5/23 4:15:00 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NUWE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nuwellis, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

      MINNEAPOLIS, May 13, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a commercial-stage medical device company dedicated to transforming care for fluid overload patients, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. First Quarter 2025 and Recent Business Highlights Nuwellis continued to advance its strategic priorities during the first quarter, delivering growth in customer categories and strengthening the foundation for broader adoption of Aquadex therapy. Higher CMS reimbursement, strong pediatric performance, and disciplined expense management position the company to capitalize on both inpatient growth and em

      5/13/25 7:00:00 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis Contracts with KDI Precision Manufacturing to Strengthen Production and Improve Operational Efficiency

      Strategic agreement is expected to reduce costs, preserve expertise, and streamline operations. WHOWHATWHEREWHENWHYNuwellis, Inc. (NASDAQ:NUWE) and KDI Precision ManufacturingOutsourcing manufacturing and assembly of key Aquadex product components.Manufacturing operations will transition to KDI's facility.May 9, 2025To strengthen operational efficiency, preserve product expertise, and reduce costs. MINNEAPOLIS, May 12, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company dedicated to transforming fluid management care, today announced it has finalized an agreement with KDI Precision Manufacturing to support the next phase of Nuwellis' growth. This strateg

      5/12/25 7:00:00 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis Expands Aquadex® for Pediatric Fluid Management to Two New Hospital Systems

      MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on fluid management solutions for patients with fluid overload, today announced a meaningful step forward for children facing fluid overload with the recent expansion of its Aquadex SmartFlow® therapy into two additional pediatric centers across the Southeastern United States. The company now has 47 pediatric centers that have adopted Aquadex therapy as part of their fluid management approach. Even in well-managed care settings, fluid overload can be a turning point in recovery for pediatric patients—who often have a narrow margin for error. When alternative therapies fall

      5/8/25 7:00:00 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NUWE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Nuwellis Inc.

      SC 13G - Nuwellis, Inc. (0001506492) (Subject)

      8/30/24 4:11:06 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Nuwellis Inc.

      SC 13G - Nuwellis, Inc. (0001506492) (Subject)

      8/2/24 4:12:11 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Nuwellis Inc.

      SC 13G - Nuwellis, Inc. (0001506492) (Subject)

      5/6/24 4:01:02 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NUWE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Nuwellis with a new price target

      ROTH MKM initiated coverage of Nuwellis with a rating of Buy and set a new price target of $17.00

      7/29/24 7:42:07 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care